QNCX250117P2500
- 0.75
- 0.000.00%
Quince Therapeutics Newsroom
Brookline Capital Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $9
Quince Therapeutics Files Mixed Securities Shelf; Shares Rise After Hours
Express News | Quince Therapeutics: Files for Mixed Shelf Offering of up to $200 Mln - SEC Filing
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Brookline Capital Initiates Coverage On Quince Therapeutics With Buy Rating, Announces Price Target of $9
Quince Therapeutics Analyst Ratings
Quince Therapeutics: Promising Investment With EryDex's Innovative Treatment and Strong Financial Position
Quince Therapeutics Management to Meet With Maxim Group
Express News | Quince Therapeutics: Regains Compliance With Nasdaq Listing Rule 5450(a)(1)
Quince Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Quince Therapeutics Q3 EPS $(0.13) Up From $(0.15) YoY
Quince Therapeutics | 8-K: Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Express News | Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Press Release: Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Maxim Group Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Maintains Target Price $6
Promising Potential of EryDex: Jason McCarthy's Buy Rating for Quince Therapeutics
Express News | D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $12 Price Target
Quince Therapeutics Presents Safety Data From Prior Phase 3 ATTeST Clinical Trial At 53rd Child Neurology Society Annual Meeting
Express News | Quince Therapeutics Presents Safety Data From Prior Phase 3 Attest Clinical Trial at 53Rd Child Neurology Society Annual Meeting
Maxim Group Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $6